ClinicalTrials.gg
RecruitingNCT06737913HAIBrave-001Updated Sep 25, 2026

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

A Phase 2 interventional study of HAI Adebrelimab and intravenous infusion (IV) of Adebrelimab (ADE) in Advanced Hepatocellular Carcinoma (HCC), sponsored by Sun Yat-sen University. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Sep 25, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 186 studies in Carcinoma, Hepatocellular by Sun Yat-sen University — 57 open to participants now, 64 under way, 10 of them phase 3. Carcinoma, Hepatocellular · Sun Yat-sen University.

Planned enrollment
100th of 160
76 · median 120
Started
2025
with 7 others
Phase 2
54 of 186
19 open now
Primary completion
2028-06
later than 57 of 63 live
Registered
172nd of 186
by date

Among the 186 studies in Carcinoma, Hepatocellular by Sun Yat-sen University, this one is the 100th largest by planned enrollment of the 160 interventional ones that give a count, is one of 8 that started in 2025, is one of 54 in phase 2, reaches primary completion later than 57 of the 63 other live ones, and was the 172nd registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 186 studies in Carcinoma, Hepatocellular by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 57 open studies →

Where they have run

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Carcinoma, Hepatocellular by Sun Yat-sen University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.

Read the detailed description

The combination of anti-PD-L1 antibody and bevacizumab has been approved as the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the overall response rate is still unsatisfactory and the prognosis of patients remains poor. Our previous retrospective analysis showed triple combination of hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen plus adebrelimab (anti-PD-L1 antibody) and bevacizumab had a high response rate for advanced stage HCC patients. More, as the PD-L1 on intrahepatic tumors is the main target of anti-PD-L1 therapy, hepatic arterial infusion of anti-PD-L1 antibody may contribute to a synergistic effect. Herein, we aimed to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma (HCC)

Keywords

  • Hepatic arterial infusion (HAI)
  • hepatic arterial infusion of FOLFOX chemotherapy
  • advanced unresectable hepatocellular carcinoma (HCC)
  • Adebrelimab (ADE)
  • Bevacizumab (Bev.)
  • intravenous infusion (IV)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the study and sign the form;
  2. Aged ≥18 years (calculated as of the date of signing the informed consent form);
  3. Diagnosed with hepatocellular carcinoma (HCC) by clinical or pathological means;
  4. Barcelona Clinic Liver Cancer (BCLC) stage C, with vascular/bile duct invasion or distant (excluding cases with Vp4-type tumor thrombus);
  5. No prior systemic therapy for HCC; or progression or residual lesions following prior local therapy for HCC (including but not limited to surgery, ablation, radiotherapy, or transarterial chemoembolization [TACE]), with an interval of at least one month between the last local treatment and enrollment;
  6. Performance Status (PS) score of 0-1 and grade A or grade B with a score of 7;
  7. No history of disease;
  8. An expected survival time of ≥3 months;
  9. At least one (per v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan must be ≥10 mm or the short axis of enlarged lymph nodes must be ≥15 mm; lesions previously treated locally can be considered target lesions if progression is confirmed per RECIST v1.1 criteria);
  10. Sufficient hematologic, hepatic, and renal function, with laboratory tests within the following parameters performed within one week prior to enrollment:

    • ≥1.5×10\^9/L;

      • count ≥75×10\^9/L;

        • ≥90 g/L;

          • Serum and AST ≤5× (ULN); ⑤ Serum creatinine ≤1.5×ULN; ⑥ (INR) \<2.3, or prothrombin time ≤ULN+6 seconds; ⑦ Albumin ≥30 g/L;

            • Total ≤3×ULN.
  11. Women of must have a negative serum or urine pregnancy test within seven days prior to study enrollment, must not be breastfeeding, and must agree to use measures during the study and for six months after its conclusion; men must agree to use contraceptive measures during the study and for six months after its conclusion.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a severe allergy to iodine contrast agents who are unable to undergo hepatic arterial infusion chemotherapy (HAIC);
  2. Use of or systemic for immunosuppressive purposes within one month prior to randomization;
  3. Active infections that cannot be effectively controlled;
  4. Severe gastroesophageal varices; untreated or incompletely treated gastroesophageal varices (with bleeding or high risk of bleeding);
  5. Presence of or bone requiring urgent surgical or radiotherapy intervention;
  6. Pregnant or suspected to be pregnant, or currently breastfeeding;
  7. Current use or recent use (within 10 days before the initiation of the study treatment) of aspirin (>325 mg/day, maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol;
  8. Thrombotic or embolic events, such as cerebrovascular accidents (including , cerebral hemorrhage, or cerebral infarction) or pulmonary embolism, occurring within six months prior to the initiation of the study treatment;
  9. Congenital or acquired immunodeficiency;
  10. History of other malignant tumors;
  11. Any of the following conditions within 12 months prior to the initiation of the study: myocardial infarction, severe/unstable angina, or congestive heart failure;
  12. Renal insufficiency requiring dialysis;
  13. History of organ transplantation;
  14. Severe acute or chronic physical or mental illnesses or laboratory abnormalities that may increase study risks or interfere with result interpretation, rendering the patient unsuitable for enrollment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    HAIBrave-001 Arm 1

    Arm 1 to receive Hepatic arterial infusion (HAI) of Adebrelimab (ADE) + intravenous infusion (IV) of Bevacizumab (Bev.) + Hepatic artery infusion chemotherapy (HAIC) with FOLFOX regimen

    Procedure: HAI Adebrelimab · Drug: intravenous infusion (IV) of Bevacizumab (Bev.) · Procedure: HAIC with FOLFOX regimen · Drug: Adebrelimab and bevacizumab maintainance treatment

  • Experimental
    HAIBrave-001 Arm 2

    Intravenous infusion (IV) of Adebrelimab (ADE) + intravenous infusion (IV) of Bevacizumab (Bev.)+ HAIC with FOLFOX regimen

    Drug: intravenous infusion (IV) of Adebrelimab (ADE) · Drug: intravenous infusion (IV) of Bevacizumab (Bev.) · Procedure: HAIC with FOLFOX regimen · Drug: Adebrelimab and bevacizumab maintainance treatment

Interventions

  • ProcedureHAI Adebrelimab

    Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)

    Also known as: HAI FOLFOX, IV Bevacizumab, IV Adebrelimab

  • Drugintravenous infusion (IV) of Adebrelimab (ADE)

    intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)

  • Drugintravenous infusion (IV) of Bevacizumab (Bev.)

    intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)

  • ProcedureHAIC with FOLFOX regimen

    HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)

  • DrugAdebrelimab and bevacizumab maintainance treatment

    The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Defined as the proportion of enrolled patients in each group who achieve either a complete response (CR) or partial response (PR) as the best response during the study, based on RECIST v1.1 criteria. Radiology imaging evaluations will be conducted every 6 weeks (or after every two treatment cycles) to assess treatment efficacy.

    Time frame: From first dose until confirmed disease progression, treatment discontinuation, or end of study, whichever occurs first; tumor imaging assessments every 6 weeks (42 ± 7 days), with confirmation of initial response at least 4 weeks later.

Secondary outcomes

  1. Progression-free survival (PFS)

    The time from the start of treatment to the first occurrence of disease progression based on RECIST 1.1 criteria or death.

    Time frame: 36 months

  2. Overall survival(OS)

    Overall Survival (OS): Patient survival status will be regularly monitored through on-site visits or telephone follow-ups after the end of study treatment until death. If a participant dies during the study, the actual time of death will be recorded.

    Time frame: 36 months

  3. Time to progression

    Time from the date of initial treatment to disease progression based on RECIST 1.1 criteria.

    Time frame: 36 months

  4. Disease control rate

    The proportion of patients with best response of complete remission, partial remission or stable disease based on RECIST 1.1 criteria.

    Time frame: 36 months

  5. Duration of response

    Refer to the time from the first documentation of complete remission or partial remission to the time of imaging-based disease progression based on RECIST 1.1 criteria.

    Time frame: 36 months

  6. Best overall response

    Refer to the best overall response between the date of enrollment to the date of disease progression or the initiation date of other sequential treatments.

    Time frame: 36 months

  7. Incidence and Severity of Adverse Events (AEs)

    Evaluate the incidence and severity of adverse events (AEs) according to NCI-CTCAE v5.0 criteria.

    Time frame: From the date of informed consent signature up to 30 days after the last dose of study treatment

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Shen L, Lin L, Zhang Y, Fang X, Lan H, Fan W. Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial. J Gastrointest Oncol. 2026 Aug 31;17(4):267. doi: 10.21037/jgo-2026-0607. Epub 2026 Jul 9. PubMed 42703324 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the informed consent does not explicitly permit data sharing with other researchers, and patient privacy and institutional data ownership policies apply. Only summary results will be published.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2028, 41 months after the start.

Of 350 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 41 months is below that.

Counting every sponsor, half of 430 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 17, 2024
StartActual
Jan 3, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameObjective response rate (ORR)6 weeks → From first dose until confirmed disease progression, treatment discontinuation, or end of study, whichever occurs first; tumor imaging assessments every 6 weeks (42 ± 7 days), with confirmation of initial response at least 4 weeks later.
Sep 25, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42703324 ↗
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42703324 ↗
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameObjective response rate (ORR)6 weeks → From first dose until confirmed disease progression, treatment discontinuation, or end of study, whichever occurs first; tumor imaging assessments every 6 weeks (42 ± 7 days), with confirmation of initial response at least 4 weeks later.
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06737913
Collaborators
Henan Provincial People's Hospital, First Affiliated Hospital of Fujian Medical University, Shanghai Zhongshan Hospital, Cancer Hospital of Guangxi Medical University, The Seventh Affiliated Hospital of Sun Yat-sen University, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, West China Hospital, Hunan Provincial Cancer Hospital, Gansu Provincial Cancer Hospital
Responsible party
Weijun Fan (Principal Investigator, Sun Yat-sen University) — Principal investigator
First posted
Dec 17, 2024
Start date
Jan 3, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Lujun Shen, M.D.
Contact
shenlj@sysucc.org.cn
86-13560365452

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion